RVBA-NOVOPrivate

Novo Nordisk

DK
Verified credentials
SBTi Validated1.5°C
Decarbonisation trajectory · all scopes
Scope 1 + 2· base 2024 · 101k tCO2eScope 3· base 2024 · 2.2M tCO2e

Headline intensities

Reporting year 2024·Values in USD ($)· normalised from DKK at FY2024 avg rate
Peer cohort: · lower is better
Revenue intensity
Carbon / $m revenue
7.79tCO2e / $m

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

no peer comparison yet
Operational intensity
Carbon / $m OpEx
tCO2e / $m

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

no peer comparison yet
Economic intensity
Carbon / $m EVIC
tCO2e / $m

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

no peer comparison yet
Asset intensity
Carbon / $m PP&E + leased
13.9tCO2e / $m

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

no peer comparison yet

Climate action evidence

1 record · 1 source
Carbon credits retired
3 tCO2e
1 retirement · FYNaN–NaN · third-party verified
By credit quality
  • Avoidance / reductions3 tCO2e(100%)
Retirement records(top 1 by volume of 1)
  • 2018-01-01 Salto Pil√£o Hydropower Plant Project Activity · verra3 tCO2e
Renewable electricity
54 %
Self-reported renewable electricity share, FY2024
Sources
  • · berkeley_voluntary_registry
Registry retirements are direct evidence; commitments are forward-looking pledges. EPA snapshot covers FY2019–FY2020.

Strategy & approach

How the firm describes its decarbonisation approach in its own words — alongside the headline numbers above. Self-reported, page-cited.

Approach to renewable energy
100% renewable electricity at production sites; suppliers transitioning

Since 2020, all Novo Nordisk production sites source 100% renewable electricity via a mix of Power Purchase Agreements (PPAs), Renewable Electricity Certificates (RECs), and Guarantees of Origin (GOs). Affiliates reached 99% renewable electricity coverage in 2024. Over 1,800 suppliers have committed to transitioning to renewable power as part of scope 3 decarbonisation. Steam/heat from biomass is conservatively excluded from renewable classification. Total energy from contractual renewable sources reached 54% in 2024.

Self-reported · FY2024 · p.56
Approach to carbon removals
Carbon removals up to 10% of baseline emissions to neutralise residual by 2045

Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of the baseline towards the net zero 2045 target, aligned with SBTi requirements and IPCC guidance. Exploring both nature-based and technology-based solutions for removing and storing GHG. Removals are not used to meet the 2033 scope 3 (-33%) interim target.

Self-reported · FY2024 · p.55
Primary decarbonisation levers
  • Circular production processes and ethanol/water reuse at API sites

    Internal reuse of ethanol at the two largest API production sites reduces use of new ethanol by ~90%. At Kalundborg, ethanol waste and yeast slurry are turned into energy and fertiliser via the Kalundborg Symbiosis. District cooling project (operational 2026) expected to save ~400,000 m³ water/year. Wastewater treatment capacity at Kalundborg being doubled by 2026.

  • Renewable electricity and heat/steam electrification in own operations

    Maintained 100% renewable electricity at production sites. Converting steam and heat in production processes to renewables by electrifying processes and covering US natural gas with biogas certificates. District cooling ring under construction at Kalundborg site (completion 2026), expected >20,000 MWh/year savings. Continuing transition away from fossil-based vehicles to BEV/PHEV.

  • Reusable injection devices and weekly-vs-daily dosing to cut plastic

    Targeting 30% reduction in plastic footprint per patient by 2033 (from 0.35 kg/patient in 2024). Converting from disposable single/multi-use pens to reusable devices (new reusable device launching 2026). Weekly basal insulin Awiqli reduces plastic ~two-thirds vs daily injection. ReMed take-back scheme for used pens operating in 7 markets (Denmark, Brazil, France, Italy, UK, Japan, Germany) with 32% return rate in Danish industry-wide scheme.

Dependent decarbonisation levers
  • Supplier renewable energy and lower-carbon raw materials (Cat 1+2)

    Categories 1 and 2 represent ~80% of scope 3. Strategy is three-pronged: (1) converting to lower-carbon raw materials and feedstocks for devices/drugs and construction; (2) process optimisation to reduce material use; (3) requiring tier 1 suppliers to transition to renewable energy. Over 1,800 suppliers committed to renewable power. Industrial partnership for e-methanol-based lower-carbon plastic in injection devices launched in 2024.

  • Lower-emission upstream and downstream distribution (Cat 4 + 9)

    Decarbonising distribution emissions across three modes: (1) air freight – converting upstream air freight to sea freight where feasible and securing Sustainable Aviation Fuel (SAF) via long-term off-take agreements; (2) sea – securing Sustainable Marine Fuel (SMF) in upstream distribution; (3) road – low-carbon road freight solutions upstream and downstream. Cat 4 fell 6% in 2024 partly due to SAF/SMF procurement curbing growth.

Targets

Near-term

3 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2Absolute20242030−1%1.5°C
0.0% reductionof −1% target · 0% there
On track
Scope 1 + 2 + 3Absolute20242030In corporate strategyabsolute-value target
Scope 3Absolute20242033−33%
0.0% reductionof −33% target · 0% there
On track

Long-term

2 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2Absolute20242045−1%1.5°C
0.0% reductionof −1% target · 0% there
On track
Scope 3Absolute20242045−90%
0.0% reductionof −90% target · 0% there
On track

Net zero

2 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2 + 3202420451.5°Cabsolute-value target
Scope 1 + 2 + 32045In corporate strategyabsolute-value target

Progress · absolute tCO2e

Scope 1 + 2 trajectory vs target
Scope 1 + 2 · 1% by 2030 · 1.5°C
ActualLinear1.5°C
Scope 3 trajectory vs target
Scope 3 · 33% by 2033
ActualLinear1.5°C

Latest news· last 5 of 18

full news log →
  • Primary: Circular production processes and ethanol/water reuse at API sites

    Internal reuse of ethanol at the two largest API production sites reduces use of new ethanol by ~90%. At Kalundborg, ethanol waste and yeast slurry are turned into energy and fertiliser via the Kalundborg Symbiosis. District cooling project (operational 2026) expected to save ~400,000 m³ water/year. Wastewater treatment capacity at Kalundborg being doubled by 2026.

    2024
  • New scope 3 reduction target: 33% by 2033 vs 2024 baseline

    In 2024, Novo Nordisk updated its decarbonisation roadmap, setting a new target of 33% absolute scope 3 reduction by 2033 from a 2024 baseline. Covers ~70% of scope 3 in accordance with SBTi provisions, submitted for SBTi validation. Aligned with well-below 2.0°C pathway (not 1.5°C).

    2024
  • Carbon removals up to 10% of baseline emissions to neutralise residual by 2045

    Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of the baseline towards the net zero 2045 target, aligned with SBTi requirements and IPCC guidance. Exploring both nature-based and technology-based solutions for removing and storing GHG. Removals are not used to meet the 2033 scope 3 (-33%) interim target.

    2024
  • Acquired three Catalent fill-finish sites for USD 11.7bn

    On 18 December 2024, Novo Nordisk acquired three fill-finish sites in US, Belgium and Italy from Novo Holdings A/S (via Catalent acquisition) for USD 11.7bn (DKK 82.1bn). Adds ~3,500 employees and significant manufacturing capacity. Mainly debt-financed via EUR 4.65bn Eurobond issuance.

    2024
  • Plastic footprint reduction target: 30% per patient by 2033

    Set new global target to reduce plastic footprint per patient by 30% by 2033, from baseline of 0.35 kg/patient in 2024. Achieved via reusable devices, circular design and less-frequent dosing.

    2024

Latest reporting year· 6 earlier years on Data-by-year tab

all years + ratios →

2026

reporting year
Financials
Revenue
OpEx
FTE
Market cap (FY-end)
Climate
Scope 1
Scope 2 (market)
Scope 2 (location)
Scope 3 total

Source documents· FY2025

all documents →
sustainability report2025
via manual upload · 4.7 MB
extractedOPEN PDF ↗